Supplementary Figure 4: The T cell and myeloid compartments are unaltered in the absence of Ly6G-tdTomato⁺ cells during recovery from EAE.

a, Total cell count of CD45⁺ cells, CD4⁺ T cells, Ly6G-tdTomato⁺ cells, CD45^hiCD11b^hiLy6G⁻ monocytes and CD45^dimCD11b^hi microglia, purified from the spinal cord of Ly6g^Cre/WT mice at early EAE recovery (day 21) treated with control antibody (rat IgG2a, clone 2A3, n = 5) or anti-Ly6G (Ly6G Ab, clone 1A8, n = 5) starting on day 12 after immunization; for gating see s. b, Cell counts of immune cell subsets purified from the spinal cord of Ly6g^Cre/WT mice at early EAE recovery (day 21) treated with 200 μg kg^–1 G-CSF (n = 5) or 5% glucose (control, n = 5) i.p. every other day, starting on day 12 after immunization; for gating see d. c, Analysis of cytokine production by intracellular cytokine staining in CD4⁺ T cells purified from spinal cord of Ly6g^Cre/WT mice treated with control antibody (rat IgG2a, n = 4) or anti-Ly6G (Ly6G Ab, n = 4) at early EAE recovery (day 23) and stimulated ex vivo with PMA/ionomycin. Symbols depict mean ± s.d. of biological replicates; Mann-Whitney U-test; **P < 0.01 (a–c). d, Gating strategy to identify different cell subsets purified from spinal cord of Ly6g^Cre/WT mice at early EAE recovery (day 21); representative plot of >30 mice, gate on analyzed single cells.